Scarica l'app Stockscreener
2.95
1.01%
-0.03
Precedente Chiudi:
$2.98
Aprire:
$3.02
Volume 24 ore:
7.66M
Relative Volume:
5.06
Capitalizzazione di mercato:
$336.44M
Reddito:
$884.00K
Utile/perdita netta:
$-103.64M
Rapporto P/E:
-2.1156
EPS:
-1.3944
Flusso di cassa netto:
$-95.45M
1 W Prestazione:
-0.67%
1M Prestazione:
-21.54%
6M Prestazione:
+10.49%
1 anno Prestazione:
-14.49%
Intervallo 1D:
$2.93
$3.13
Intervallo di 1 settimana:
$2.865
$3.13
Portata 52W:
$1.955
$6.16
Perspective Therapeutics Inc Stock (CATX) Company Profile
Nome
Perspective Therapeutics Inc
Settore
Industria
Telefono
509-375-1202
Indirizzo
350 Hills Street, Suite 106, Richland
Compare CATX vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
2.95 | 336.44M | 884.00K | -103.64M | -95.45M | -1.3944 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-19 | Iniziato | Piper Sandler | Overweight |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-10-10 | Iniziato | BTIG Research | Buy |
| 2025-03-13 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-11-25 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-01 | Iniziato | Wedbush | Outperform |
| 2024-09-25 | Iniziato | Truist | Buy |
| 2024-07-25 | Iniziato | BofA Securities | Buy |
| 2024-05-09 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Perspective Therapeutics Inc Borsa (CATX) Ultime notizie
Perspective Therapeutics Inc (CATX) Institutional Confidence - TradingKey
Perspective Therapeutics Inc (CATX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Perspective Therapeutics Inc (CATX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Perspective Therapeutics Inc - TradingKey
Perspective Therapeutics Inc (CATX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Analysts Offer Insights on Healthcare Companies: enGene Holdings (ENGN) and Intellia Therapeutics (NTLA) - The Globe and Mail
Perspective Therapeutics Inc (CATX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Enliven Therapeutics Surges on Promising Leukemia Drug Trial ResultsEarnings Outlook Update - newsline.com
Perspective Therapeutics Doses First Meningioma Patient in Phase 1/2a Study Cohort - Moomoo
CATX Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Clinical ProgressForward Guidance Trends - newsline.com
Perspective Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Radioligand Therapy Market is Expected to Grow Rapidly by 2036, Estimates DelveInsight - openPR.com
Perspective Therapeutics (CATX) Institutional Ownership 2026 - MarketBeat
Wedbush Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trial - Yahoo Finance
Perspective Therapeutics (CATX) Initiates Meningioma Patient Stu - GuruFocus
Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study - The Manila Times
Targeted alpha therapy trial doses first patient for common brain tumor - Stock Titan
Perspective Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Perspective Therapeutics (CATX) Gets a Buy from Oppenheimer - The Globe and Mail
Perspective Therapeutics (CATX) Gets a Hold from Bank of America Securities - The Globe and Mail
Perspective Therapeutics Advances Next-Generation 212Pb Radiopharmaceuticals for Solid Tumor Oncology Treatment - Minichart
Perspective Therapeutics Highlights Progress in Alpha Radiopharmaceutical Pipeline - TipRanks
Perspective updates corporate presentation detailing 212Pb radiopharmaceutical pipeline and regional production strategy - TradingView
Perspective Therapeutics (NYSE: CATX) outlines 212Pb cancer pipeline update - Stock Titan
Vivos Therapeutics (VVOS) Gains 4.5% as Stock Tests Key Resistance at $0.73Growth Stock Picks - thelegaladvocate.com
Perspective Therapeutics (CATX) Slides 2.72% as Stock Tests Key Support LevelsBollinger Squeeze - newsline.com
Edgewise Therapeutics Inc. (EWTW) Q1 2026 Earnings: Narrower Losses Bolster Investor SentimentRevenue Estimate Trend - thelegaladvocate.com
Cullinan Therapeutics (CGEM) Retreats 1% as Stock Approaches Support ZoneLarge Cap Trends - thelegaladvocate.com
Phanes Therapeutics Announces Updated Phase 2 Clinical Trial Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline Treatment of Metastatic PDAC at the 2026 ASCO Annual Meeting - Yahoo Finance
Perspective Therapeutics Inc. (CATX) Q1 2026 Earnings: Narrower-than-Expected Loss Amid Clinical ProgressEPS Surprise History - thelegaladvocate.com
Fluidra Appoints Juan Graham as Chief Financial Officer - hrtoday.in
Aprea Therapeutics (APRE) Edges Higher Amid Light Trading; Key Resistance at $0.99 in FocusOBV Divergence - thelegaladvocate.com
Perspective Therapeutics, Inc. 8-K Filing Details for May 27, 2026: Company Information and SEC Compliance - Minichart
Molecular Targeting Technologies Reports Clinical Data Supporting Two-Cycle EBTATE and Enhanced Tumor Targeting in GEP-NET Patients at SNMMI 2026 - Yahoo Finance
Perspective Therapeutics shareholders approve directors and governance items - TipRanks
Shareholders of Perspective Therapeutics (NYSE: CATX) back board, auditor - Stock Titan
Perspective Therapeutics Inc. (CATX) Q1 2026 Earnings: Loss Narrows Sharply, Stock Gains 2.84%Profitability Analysis - thelegaladvocate.com
A Quick Look at Today's Ratings for Perspective Therapeutics(CATX.US), With a Forecast Between $8 to $15 - Moomoo
Perspective Therapeutics (CATX) Gains 2.84% as Stock Nears Key Resistance at $4.18High Yield Stocks - newsline.com
Perspective Therapeutics Inc. (CATX) Q1 2026 Earnings: EPS Beat by 17% as Pre‑Revenue Biotech Advances Radiopharmaceutical PipelineEarnings Per Share - newsline.com
Bank of America Securities Reaffirms Their Hold Rating on Perspective Therapeutics (CATX) - The Globe and Mail
BofA Securities Maintains Perspective Therapeutics(CATX.US) With Hold Rating, Maintains Target Price $6 - Moomoo
Piper Sandler Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Perspective Therapeutics Presents Positive Clinical Data for [212Pb] Radiopharmaceuticals in Melanoma, Neuroendocrine, and Solid Tumors at ASCO 2026 - Minichart
Perspective Therapeutics Showcases Strong Interim Radiopharma Data - TipRanks
Perspective Therapeutics (NYSE: CATX) highlights new 212Pb trial data at 2026 ASCO - Stock Titan
Perspective Therapeutics, Inc. Reports Positive Updates on Clinical Programs at ASCO 2026, Highlighting Efficacy and Safety of [212Pb]VMT-α-NET, [212Pb]VMT01, and [212Pb]PSV359 - Quiver Quantitative
Early melanoma trial sees tumor responses in hard-to-treat patients - Stock Titan
UBS Maintains Perspective Therapeutics (CATX) Buy Recommendation - MSN
Earnings Preview: CATX to Report Financial Results Post-market on May 11 - Moomoo
Perspective Therapeutics Inc Azioni (CATX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.93%
Capitalizzazione:
|
Volume (24 ore):